Comparing allergy shots and biologic for dust mite asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study compares two allergy treatments for people with moderate asthma caused by dust mites. It tests whether a biologic injection (omalizumab) alone is as effective as combining it with allergy drops under the tongue (sublingual immunotherapy).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your total IgE level (a blood test for allergies) must be between 30 and 700 IU/mL.
- You have moderate, partially controlled asthma that is triggered by house dust mites and occurs year-round.
- Your lung function (FEV1) must be above 70% of the normal value.
- You must have a positive skin prick test for at least one type of dust mite (D. pteronyssinus or D. farinae).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
This trial tests a new allergy shot that may reduce symptoms of dust mite allergies, like sneezing, runny nose, and itchy eyes. It might also help with mild asthma caused by dust mites.
This trial tests if omalizumab (a drug that blocks allergy reactions) can help people with multiple food allergies. You might qualify if you have severe allergies to at least two foods like peanut, tree nuts, egg, or milk.
This study tests if omalizumab, an allergy medicine, can help people with COPD who are allergic to common indoor allergens and have had recent flare-ups. It aims to see if reducing allergic reactions can improve COPD control.
This trial tests allergy shots for children with dust mite allergies causing rhinitis or asthma. It aims to see if guiding treatment with detailed allergy testing leads to better results.
This trial tests whether adding an allergy immunotherapy tablet (which helps your immune system get used to dust mites) to a biologic treatment (tezepelumab, which reduces airway inflammation) can keep severe asthma under control better than the biologic alone. It may help reduce asthma attacks and improve daily symptoms.
Hear when a new Asthma, Allergic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.